ASCO Genitourinary Cancers Symposium


 

ASCO GU 2022 OS in mHSPC Treated With Enzalutamide + ADT by High/Low Disease Volume and Progression to (de Novo) mHSPC (M0/M1 at Diagnosis): Post Hoc Analysis of the Phase 3 ARCHES Trial

53 views
March 2, 2022
Comments 0
Login to view comments. Click here to Login